|
Type of Company:
Type:
|
Company
|
Ownership: |
Privately Held |
Company Size: |
50-99 Employees In BC (50-99 Total)
50-99 In BC (50-99 Total)
|
Revenue: |
$15.60 Million CAD |
Year Founded: |
1987 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
XENON, biopharmaceutical, phenotypes, drug development, medicines
|
Profile Views: |
2,423 Company Profile Views |
|
|
XENON® (NASDAQ: XENE) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes.
We apply our expertise to predict which phenotypes are caused by single-gene defects. By identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. Given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
|
|
|
Date |
Type |
Amount |
Investors |
Jan 27, 2020 |
Unattributed |
$60 Million CAD |
Public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share. |
Date |
Type |
Amount |
Investors |
Jan 27, 2020 |
Unattributed |
$60M CAD |
Public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share. |
|
|
Want More Xenon Pharmaceuticals Inc. News? 1 2 3 4 5 6
|
Next »
|
|
|
|
|
Jan 19, 2021
|
Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021
|
Dec 16, 2020
|
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs
|
Oct 9, 2020
|
Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE
|
Aug 25, 2020
|
Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer
|
Aug 13, 2020
|
Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
|
May 28, 2020
|
Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
|
Mar 31, 2020
|
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Mar 10, 2020
|
Xenon Pharmaceuticals Reports 2019 Financial Results and Provides Corporate Update
|
Jan 28, 2020
|
Xenon Pharmaceuticals Announces Closing of its $60.0 Million Public Offering of Common Shares
|
Jan 24, 2020
|
Burnaby-based Xenon Pharmaceuticals Announces Planned $60.0 Million Financing (Public Offering of Common Shares)
|
|
1 - 10 of 71 results
|
|
 |
|
|
|
Share This Company Profile |
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|